Tracks outcomes of olaparib use in advanced prostate cancer patients
Observes patients with advanced prostate cancer treated with olaparib in routine practice.
Key facts
- Who runs it
- Santa Chiara Hospital
- Where
- Naples and Trento, ItalySee the 2 sites
- Trial code
- Registry title
- Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
- Status
- Recruiting
- People taking part
- 3,000 people, planned
- Started
- 1 Jan 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- Olaparib
- Record updated
- 11 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for men with prostate cancer that has spread and no longer responds to hormone-lowering treatment. They must have a BRCA gene change and be treated with olaparib in routine care.
- Sex
- Men only.
- Disease stage
- Metastatic castration-resistant prostate cancer (cancer that has spread and no longer responds to hormone-lowering treatment).
- Earlier treatment
- Must be treated with olaparib in clinical practice, outside a clinical trial.
- Biomarker or test result
- BRCA mutation.
Main reasons for not taking part
- Olaparib treatment given in a clinical trial
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice
Who cannot take part
- Olaparib treatment in a clinical trial
Where in Italy
- Sabrina RossettiNaples, ItalyContact: Sabrina RossettiTaking people
- Orazio CaffoTrento, ItalyContact: Orazio CaffoTaking people
About the trial
What the trial wants to find out
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
The group in the trial
- mCRPC treated with olaparib
mCRPC patients who receive olaparib in daily clinical practice
Treatment: Olaparib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study
- Plain-language title
- Tracks outcomes of olaparib use in advanced prostate cancer patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 February 2025